Active Ingredient History
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Biliary Tract Neoplasms (Phase 3)
Biomarkers, Pharmacological (Phase 2)
Breast Neoplasms (Phase 2)
Carcinoma, Hepatocellular (Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 3)
Carcinoma, Ovarian Epithelial (Phase 2)
Carcinoma, Renal Cell (Phase 1/Phase 2)
Colonic Neoplasms (Phase 2)
Colorectal Neoplasms (Phase 2)
Drugs, Investigational (Phase 2)
Drug Therapy (Phase 2)
Endometrial Neoplasms (Phase 2)
Endostatins (Phase 2)
Esophageal Neoplasms (Phase 2)
Esophageal Squamous Cell Carcinoma (Phase 2)
Fibrosarcoma (Phase 2)
Gallbladder Neoplasms (Phase 2)
Healthy Volunteers (Phase 1)
Hepatitis B, Chronic (Phase 2)
HIV Infections (Phase 2)
Immune Checkpoint Inhibitors (Phase 2)
Immunotherapy (Phase 2)
Induction Chemotherapy (Phase 2)
Lung Neoplasms (Phase 2)
Melanoma (Phase 2)
Mutation (Phase 2)
Nasopharyngeal Carcinoma (Phase 2)
Neoadjuvant Therapy (Phase 2)
Neoplasm Metastasis (Phase 2)
Neoplasms (Phase 2)
Neoplasms, Multiple Primary (Phase 2)
Radiotherapy (Phase 2)
Rectal Neoplasms (Phase 3)
Sarcoma (Phase 2)
Stomach Neoplasms (Phase 3)
Thymoma (Phase 2)
Uterine Cervical Neoplasms (Phase 2)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue